Mindray Medical was surveyed by 476 institutions in one week! Last week, institutions gathered to investigate pharmaceutical stocks

【Pharmaceutical Network Pharmaceutical Stock Market】 Last week, institutions gathered to investigate pharmaceutical stocks, and the data showed that among the popular research stocks, 33 companies attracted more than 100 huge research groups
.

Among them, there are 5 companies involved in the pharmaceutical and biological industry, and the medical device subdivision sector occupies 3 seats, namely Mindray Medical, Kaili Medical and Yuyue Medical
.

Mindray Medical obtained 476 institutions It is reported that after the disclosure of the semi-annual report, Mindray Medical attracted 476 institutions and a total of more than 1,000 participants
on August 22.

Became a research unit
that attracted institutional attention last week.

Participating institutions include 87 public funds, 57 securities companies, 23 insurance funds and 164 private and foreign institutions
.

In an institutional survey, Mindray Medical said that due to the impact of the epidemic in overseas developing countries in the first quarter of 2021 and the pressure of the base of European medical shortcomings, the overseas market in the first quarter of this year only grew
by single digits year-on-year.

However, since entering the second quarter, the pressure on the base has been significantly alleviated, and the outpatient volume, hospitalization volume and surgical volume of hospitals under the new normal of overseas anti-epidemic have been fully restored, so conventional businesses such as IVD reagents, ultrasound, and anesthesia machines have achieved recovery, making the overseas market growth nearly 30% in the second quarter, of which the growth rate of developing countries has also rebounded to more than
40%.

Mindray Medical also said in the survey that the company continues to ensure high investment in research and development, continuous enrichment of products, continuous iteration of technology, especially in the high-end continuous
breakthroughs.

In the first half of 2022, R&D investment was 1.
46 billion yuan, an increase of 25% year-on-year, of which R&D expenses were 1.
35 billion yuan, an increase of 27%
year-on-year.

For example, in the field of in vitro diagnostics, the fully automatic biochemical analyzer BS-600M, the small biochemical immune pipeline M1000, the automatic blood cell analyzer BC760 and BC-760CS, the new generation of high-end coagulation analyzer CX-9000 and supporting reagents and other new products have been launched
.

According to the semi-annual performance report of Mindray Medical, in the first half of this year, the company's operating income increased by 20.
17% year-on-year to 15.
356 billion yuan, and the net profit increased by 21.
71% year-on-year to 5.
288 billion yuan
.

In addition, according to statistics, since 2022, the total number of Mindray medical reception institutions has reached 3876 times
.

Kaili Medical received a survey of 301 institutions on August 24, 2022, and the types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, securities companies, and sunshine private equity institutions
.

In the institutional survey, Kaili Medical said that in the first half of 2022, the company's various business developments are in line with the planning formulated at the beginning of the year, the ultrasound business grows steadily, the endoscopic business maintains a high growth rate, and the overall company's revenue increases significantly, and the net profit performance is better
.

The company believes that the net profit growth rate in the first half of the year is higher, mainly due to the "scale effect", from the second half of 2021, the company's financial data has gradually shown the trend of entering the "scale effect" stage, and confirmed this trend
for three or four consecutive quarters.

The scale effect includes: 1, with the company's early large market investment, research and development investment, a large number of new products listed, the company's product recognition is getting better and better, the company's marketing channel construction is also improving, the company's revenue continues to grow, of which ultrasound steady growth, endoscopic equipment rapid growth; 2.
The company's endoscopic product line has begun to generate profits, and with the increase in the proportion of endoscopic high-end products and the expansion of revenue scale, the gross profit margin level of endoscopy continues to increase; 3.
After the rapid formation and expansion of the company's team in the first two years, the current team expansion has entered a stable period, and the growth of various expenses has been flat; As revenue grew, R&D and sales expense ratios gradually declined
.

4, the company's overall gross profit margin is stable, with the release of high-end products, the proportion increases, the company's gross profit margin can still rise steadily; The company's overall net profit margin has rebounded to a relatively good normal
.

Yuyue Medical received 142 institutional surveys On August 24, 2022, Yuyue Medical was surveyed by 142 institutional units, including QFII, insurance companies, others, fund companies, overseas institutions, securities companies, and sunshine private equity institutions
.

In the institutional survey, Yuyue Medical said that in the first half of this year, the company's blood glucose plate achieved a growth of 35.
29%, and online, offline and overseas channels have achieved growth
.

At present, the company in Southeast Asia, South America, North Africa and other regions, thanks to the company's good performance in related business in recent years, with some local medical institutions, the government to build a good relationship of trust and cooperation, the number of developed customers has gradually increased, to a certain extent to accelerate the process
of product introduction, territorial registration and other matters in various business segments.

Yuyue Medical also said that since the second half of last year, the company has accelerated the construction
of personnel organizations around overseas business strategies and research and development layouts.

In the past, the company's overseas business employees were relatively small, and with the in-depth layout of the export business, the team personnel increased; The company has always attached importance to R & D investment, the key business line R & D team has been optimized and strengthened, at the same time, the company's innovation research institute has also increased to more than 40 employees, after the acquisition of Kailite, the relevant sectors have been supplemented
.

The company currently has an export team of more than 100 people, more than half of the overseas localization employees, the future is expected that the entire team will gradually optimize and expand to adapt to the strategic needs of export sales, the construction of related systems is being upgraded in
an orderly manner.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.